Daniel Engelman Selected Research

Impetigo (Impetigo Contagiosa)

9/2022	Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis.
5/2022	Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018-2020.
3/2021	Prevalence of scabies and impetigo in school-age children in Timor-Leste.
1/2021	Emerging Treatment Strategies for Impetigo in Endemic and Nonendemic Settings: A Systematic Review.
10/2020	Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin.
1/2020	Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study).
1/2019	Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Engelman Research Topics

Disease

17	Scabies (Sarcoptic Mange) 09/2022 - 04/2013
7	Impetigo (Impetigo Contagiosa) 09/2022 - 01/2019
6	Rheumatic Heart Disease (Rheumatic Heart Diseases) 01/2022 - 01/2016
5	Filarial Elephantiasis (Lymphatic Filariasis) 05/2022 - 04/2013
3	Neglected Diseases 01/2021 - 10/2018
2	Infections 05/2022 - 12/2015
2	Trachoma 01/2019 - 10/2018
1	Soft Tissue Infections 05/2022
1	Disease Progression 01/2022
1	Larva Migrans (Cutaneous Larva Migrans) 01/2021
1	Myiasis (Myiases) 01/2021
1	Parasitic Diseases (Parasitic Disease) 01/2021
1	Strongyloidiasis 01/2021
1	Trichuriasis 01/2021
1	Abscess 01/2019
1	Furunculosis (Boils) 01/2019
1	Cushing Syndrome 08/2018
1	Skin Diseases (Skin Disease) 11/2016
1	Myocardial Infarction 10/2016
1	Ischemia 10/2016
1	Stroke (Strokes) 10/2016
1	Sepsis (Septicemia) 12/2014

Drug/Important Bio-Agent (IBA)

11	Ivermectin (Mectizan)FDA Link 05/2022 - 04/2013
3	Permethrin (Ambush)FDA LinkGeneric 05/2022 - 10/2018
3	Azithromycin (Zithromax)FDA LinkGeneric 10/2020 - 10/2018
2	Albendazole (Albenza)FDA Link 05/2022 - 11/2021
2	Diethylcarbamazine (Hetrazan)FDA Link 05/2022 - 11/2021
2	Penicillin G Benzathine (Benzathine Benzylpenicillin)FDA Link 01/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 10/2020 - 10/2018
1	insulin receptor-related receptor (IRR)IBA 05/2022
1	ozenoxacinIBA 01/2021
1	retapamulin FDA Link 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2021
1	Tetracycline (Achromycin)FDA LinkGeneric 10/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2018
1	SteroidsIBA 08/2018

Therapy/Procedure

17	Mass Drug Administration 09/2022 - 04/2013
3	Antibiotic Prophylaxis 01/2022 - 01/2016
2	Secondary Prevention 01/2017 - 02/2016
1	Anesthesia 10/2016
1	Length of Stay 10/2016
1	Critical Care (Surgical Intensive Care) 12/2014